← About this guide

FREE PREVIEW

Semax and Selank

Human abstracts, animal research and translation limits.

3 sectionsEvidence: 2026-10-27 selected-source checks; not a systematic search

AI-assisted editorial edition · Independent clinical review pending.

Before you read

This selected-source guide explains research for education. It is not a diagnosis, prescription or personal treatment plan. Do not start, stop or change medicines, combine products, or delay care because of this guide. Discuss proposed uses and interactions with a qualified clinician and pharmacist. It does not establish a clinician-patient relationship.

What this edition can and cannot answer

A selected-source research-reading edition separating animal/laboratory findings, human abstract records, product identities and unanswered clinical questions; no therapeutic or combination instructions.

  • Animal behavioral tests, gene-expression changes and brain-imaging differences do not establish meaningful cognitive or anxiety benefit for a consumer.
  • Key human reports remain abstract-only in the reviewed pilot; full methods, harms, cohort overlap and bilingual scientific review are incomplete. Separate-agent reports do not establish a Semax/Selank combination benefit.
  • Bounded source closure checked 27 October 2026 using the named full reports, publisher/PubMed records and available companion documents. This is not a systematic literature search or exhaustive integrity review. Protocol comparisons and specified access, overlap and translation checks remain unfinished.
  • AI-assisted editorial draft. Human editorial, qualified independent clinical, legal, reader-test and accessibility reviews are pending. Purchases and PDF downloads are not yet available.

SECTION 01

Semax and Selank

Cognition and anxiety claims often connect a biological signal to an everyday benefit. This guide shows where that connection is supported by a source and where human evidence still needs to be obtained and appraised. Use it to prepare a precise research question and a professional conversation.

Contents

SECTION 02

What the selected record can answer

Source typeConcrete selected exampleWhat remains unanswered
Human abstract [1]Brain connectivity after Semax, Selank or placebo in healthy participantsMeaningful cognition, symptom relief and durability
Rat brain genes [2][3]Gene-expression changes after experimental exposureA reliable human benefit or established clinical mechanism
Rat behavior [4]Selank and diazepam under stress and non-stress conditions; some non-stress indicators worsenedVehicle and locomotion changes complicate interpretation; no human combination-safety conclusion
Human anxiety abstract [5]Selank versus medazepam in anxiety/neurasthenia patientsVerified clinical magnitude, allocation, complete harms and durability

This is an evidence map, not a ranking of products. Its purpose is to keep the model, intervention and measured endpoint attached to each statement. An animal result can justify another experiment without predicting the chance that a person will benefit.

Source-specific examples [1][2][3][4][5]; FDA context [6]. The connectomic report is one paper, not two independent studies. Qualified independent review remains pending.

SECTION 03

Sources, gaps and edition record

Selected sources; three rat reports checked in full. Human imaging (2020) and anxiety (2008) reports remain abstract-only. A duplicate imaging citation was merged. This is not a systematic review.

The selected reports leave unresolved human methods, harms and analysis gaps [1][5], plus bilingual and cohort checks for other clinical leads. No independent clinical, legal or translation approval is recorded.

Report a source or edition correction · Educational-use policy

FOLLOW THE EVIDENCE

Sources and reading limits

  1. Panikratova et al. Functional Connectomic Approach to Studying Selank and Semax Effects (2020)

    Human imaging example; separate-agent conditions.

    PMID32342318; PubMed abstract and subscription publisher preview checked 27 October 2026; full report not acquired.

  2. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis

    Rat ischemia gene-expression example; appraisal pending.

    Results p2; Methods p10; printed abstract p1.

  3. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

    Animal mechanism example; no clinical efficacy.

    Gene-expression Results p3; rat frontal cortex identified p1.

  4. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

    Rat behavior comparison; no human combination advice.

    Abstract/Results p1; animal groups/routes p2.

  5. Zozulia et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (2008)

    62-patient active-comparator abstract; clinical methods/harms unresolved.

    PMID18454096; Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38–48; PubMed abstract checked 27 October 2026; full report not acquired.

  6. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    United States compounding context; not global legal status.

    Semax/Selank entries; checked 27 October 2026.

Edition and corrections

Web reading edition: 4 November 2026. Manuscript prepared: 2026-10-27. This web-format update does not represent a new literature search or completed clinical review.

Edition: PA-GUIDE-SEMAX-SELANK-2026-10-27-0.2-REVIEW-DRAFT

Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.

Report a correction →

Explore all consumer guides